ArticleCase reports in psychiatry2026
Clinical Consequences of Inadvertent Intramuscular Administration of Subcutaneous Risperidone Formulation.
Article in Case reports in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long-acting injectable (LAI) antipsychotics have been predominately administered intramuscularly (IM). Recently, subcutaneous (SC) formulations have been developed. Information regarding what occurs when the drug is not administered properly is lacking. A 23-year-old woman with bipolar disorder, currently manic with psychosis, was responding well to a combination of lithium and risperidone. She accepted a LAI of SC risperidone, but the drug was administered IM by error. The improvement she had already displayed was partially lost, and oral risperidone had to be reinitiated. She complained of mild pain at the injection site, but no other adverse consequences were noted. When a SC formulation is administered IM, it results in mild muscle pain, and unpredictable release of risperidone, but no other notable clinical problems.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.